60
Participants
Start Date
February 28, 2006
Primary Completion Date
April 30, 2009
Study Completion Date
July 31, 2010
SU011248/Trastuzumab
SU011248 will be administered orally, starting dose of 37.5 mg daily on a continuous regimen. Trastuzumab will be administered weekly (loading dose 4 mg/kg followed by weekly 2mg/kg) or every 3 weeks (loading dose 8 mg/kg followed by 6mg/kg q3w). Study treatment should continue until progression, withdrawal for other reasons, or for up to 18 months following which patients requiring continued access will be offered SU011248 on a separate protocol.
Pfizer Investigational Site, Ottignies
Pfizer Investigational Site, Wilrijk
Pfizer Investigational Site, New York
Pfizer Investigational Site, Newark
Pfizer Investigational Site, Wilmington
Pfizer Investigational Site, Besançon
Pfizer Investigational Site, Madrid
Pfizer Investigational Site, Fort Lauderdale
Pfizer Investigational Site, Montgomery
Pfizer Investigational Site, Memphis
Pfizer Investigational Site, Memphis
Pfizer Investigational Site, Southaven
Pfizer Investigational Site, Corinth
Pfizer Investigational Site, Valencia
Pfizer Investigational Site, Munster
Pfizer Investigational Site, Harvey
Pfizer Investigational Site, Tinley Park
Pfizer Investigational Site, Lyon
Pfizer Investigational Site, Lafayette
Pfizer Investigational Site, New Iberia
Pfizer Investigational Site, Las Vegas
Pfizer Investigational Site, Saint-Cloud
Pfizer Investigational Site, Newark
Pfizer Investigational Site, Toronto
Pfizer Investigational Site, Greenfield Park
Pfizer Investigational Site, Montreal
Pfizer Investigational Site, Barcelona
Lead Sponsor
Pfizer
INDUSTRY